HALIFAX, Feb. 15 /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ:MMIRF) the global market leader in rapid flow- through diagnostic technology, today announced that internationally renowned Stanford Medical University, Duke Medical University and Johns Hopkin's Medical Research University are currently using MedMira's FDA approved Reveal(TM) G2 Rapid HIV-1 Antibody Test's (Reveal(TM) G2) in their central labs. These leading medical research universities have chosen Reveal(TM) G2 over other FDA- approved rapid HIV tests after routine evaluations. A recently released report by Stanford and Duke Universities shows the cost benefits of increased national HIV testing in the United States.
MedMira had announced previously that Reveal(TM) G2 was the number one choice for U.S. hospitals for the second year running, based on results of an independent United States CDC study (January 18th, 2005). While rapid HIV testing is still an emerging market in the U.S., MedMira's Reveal(TM) G2 has quickly become the leading rapid HIV test in U.S. hospitals due to its ease of use and quick time to obtain test results (only 3 minutes), compared to the other FDA-approved tests which require 10 to 40 minutes to obtain results.
With a China CDC study placing MedMira's rapid test as number one for quality and consistency of results and the South African Medical Research Council's recent rating of MedMira's MiraWell(TM) HIV Test as the primary test of choice, MedMira is gaining a strong international reputation in the global healthcare market. MedMira's most recent advancement was the launch of its Over the Counter (OTC) MiraCare(TM) Rapid HIV Test in Hong Kong and Macao (released January 24th, 2005).
Says Hermes Chan, president and COO of MedMira "Our line of rapid HIV tests continues to receive the highest marks in trials and evaluations worldwide; from countries with highly respected healthcare systems, like the United States, China and South Africa, to smaller nations with very little infrastructure." Chan continues, "This recent study by Stanford and Duke Universities proves that the need for rapid HIV testing is increasing and MedMira is confident that we will continue to lead the way in providing reliable rapid HIV testing products to the world."
MedMira is the only rapid HIV test manufacturer in the world to receive regulatory approvals from the U.S. FDA, Health Canada and the Chinese SFDA. Other leading health units around the world using MedMira's rapid HIV tests include the Canadian Armed Forces, United States Marine Corps, China Provincial Blood Banks, Stanford Medical University, Duke Medical University and Johns Hopkin's Medical Research University.
MedMira is the leading global manufacturer and marketer of in vitro flow-though rapid diagnostic tests for the clinical laboratory market. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid HIV Tests, respectively. For more information visit MedMira's website at http://www.medmira.com/.
MedMira's Reveal(TM) G2 and MiraWell(TM) rapid HIV tests are currently used in clinical laboratories and hospitals where professional counseling and patient treatment are immediately available.
MedMira markets its rapid tests worldwide in such countries as the United States, Canada, South Africa and China. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Beijing, China.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.